- Chemicals for Life Science -

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Home > RNA Delivery > Cationic/Ionizable Lipids > Ionizable Lipids for bone marrow-targeted delivery

Lipid A10

Cat. No.: DC68150 Featured

Chemical Structure

For research use only. We do not sell to patients.

We match the best price and quality on market.
Email:order@dcchemicals.com sales@dcchemicals.com
Tel:+86 21 58447131

Get Quotation Now

We are official vendor of:

More than 5000 active chemicals with high quality for research!

Field of application

A10 (Compound 16) is a diketopiperazine‑based ionizable lipid disclosed in WO 2025/217298 A1 (PCT/US2025/023899) developed by NAVA Therapeutics that enables potent, cell‑selective in vivo delivery of mRNA and nucleic acids without targeting ligands. It forms stable, well‑tolerated lipid nanoparticles (LNPs) that preferentially transfect hematopoietic stem cells (HSCs), bone marrow progenitors, lung epithelium, endothelium, and immune cells while minimizing liver off‑target delivery. In both mice and non‑human primates, A10‑containing LNPs drive functional mRNA expression and gene editing in CD34⁺ HSCs at clinically relevant low doses (0.25–1.0 mg/kg), supporting in vivo HSC gene therapy without ex vivo manipulation.

Chemicals Properties Biological activity Related products COA MSDS Datasheet

Cas No.:
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	WO 2025/217298 A1 (PCT/US2025/023899)

Cat. No.	Product name	Field of application
DC68150	Lipid A10	A10 (Compound 16) is a diketopiperazine‑based ionizable lipid disclosed in WO 2025/217298 A1 (PCT/US2025/023899) developed by NAVA Therapeutics that enables potent, cell‑selective in vivo delivery of mRNA and nucleic acids without targeting ligands. It forms stable, well‑tolerated lipid nanoparticles (LNPs) that preferentially transfect hematopoietic stem cells (HSCs), bone marrow progenitors, lung epithelium, endothelium, and immune cells while minimizing liver off‑target delivery. In both mice and non‑human primates, A10‑containing LNPs drive functional mRNA expression and gene editing in CD34⁺ HSCs at clinically relevant low doses (0.25–1.0 mg/kg), supporting in vivo HSC gene therapy without ex vivo manipulation.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.